Kenneth Allen Myszkowski, Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 72,334 shares at $19.68 ($1.4M) on 2025-01-06, disclosed to the SEC on 2025-01-07.
Scheduled sale ($1.4M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.68 | 17,765 | $350K | 24.4% |
| 2 | $19.68 | 17,765 | $350K | 24.4% |
| 3 | $20.10 | 9,402 | $189K | 13.2% |
| 4 | $20.10 | 9,402 | $189K | 13.2% |
| 5 | $19.69 | 10,000 | $197K | 13.8% |
| 6 | $19.70 | 8,000 |
| $158K |
| 11.0% |
| Total | $19.79 avg | 72,334 | $1.4M | 100% |
| Filing → |
| ARWR | SELL | 2023-06-29 | $543K | — | Filing → |
| ARWR | SELL | 2022-12-30 | $1.2M | — | Filing → |
| ARWR | SELL | 2022-01-06 | $2.9M | — | Filing → |